Cytokines as predictors of severity in acute pancreatitis: Editorial

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 12, 1998, Pages 1177-1179

  Balakrishnan, V ^a   Philip, M ^a  

^a Sree Sudheendra Medical Mission Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; LEUKOCYTE ELASTASE; PHOSPHOLIPASE A2; SCATTER FACTOR; THROMBOCYTE ACTIVATING FACTOR; TRYPSINOGEN; TUMOR NECROSIS FACTOR;

ACUTE PANCREATITIS; CYTOKINE PRODUCTION; DISEASE SEVERITY; EDITORIAL; HELPER CELL; HUMAN; INFLAMMATION; MORTALITY; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032417771     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1998.01781.x     Document Type: Editorial

References (32)

1. 1 Fernadez‐del Castillo C, Rattner DW, Warsaw AL. Acute pancreatitis. Lancet 1993 ; 342: 475– 9.
2. 2 Debeaux AC, Palmer KR, Carter DC. Factors influencing morbidity and mortality in acute pancreatitis. An analysis of 279 cases. Gut 1995 ; 37: 121– 6.
3. 3 Kusske AM, Rongione AJ, Reber HA. Cytokines and acute pancreatitis. Gastroenterology 1996 ; 110: 639– 42.
4. 4 Deitch EA. Multiple organ failure: Pathophysiology and potential future therapy. Ann. Surg. 1992 ; 216: 117– 34.
5. 5 Sanfey H, Broe PJ, Cameron JL. Experimental ischemic pancreatitis: Treatment with albumin. Am. J. Surg. 1985 ; 150: 297– 300.
6. 6 Formela LJ, Galloway SW, Kingsnorth AN. Inflammatory mediators in acute pancreatitis. Br. J. Surg. 1995 ; 82: 6– 13.
7. 7 Dominguez‐Munoz JE, Carballo F, Garcia MJ et al. Clincial usefulness of polymorphonuclear elastase in predicting severity of acute pancreatitis: Results of a multicentre study. Br. J. Surg. 1991 ; 78: 1230– 4.
8. 8 Newman W, Beall LD, Carson CW et al. Soluble E‐selectin is found in supernatants of activated endothelial cells and is elevated in serum of patients with septic shock. J. Immunol. 1993 ; 150: 644– 54.
9. 9 Smith KA, Lachman LB, Oppenheim JJ, Favata MF. The functional relationship of the interleukins. J. Exp. Med. 1980 ; 151: 1551– 6.
10. 10 Curley P, Nestor M, Collins K et al. Decreased interleukin‐2 production in murine acute pancreatitis: Potential for immunomodulation. Gastroenterology 1996 ; 110: 583– 8.
11. 11 Hirano T, Taga T, Yamasaki T, Matsuda T. A multifunctional cytokine (IL‐6/BSF‐2) and its receptor. Int. Arch. Allergy Appl. Immunol. 1989 ; 88: 29– 33.
12. 12 Tracey KJ, Beutler B, Lowry SF et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986 ; 234: 470– 4.
13. 13 Fiorentino D, Ziotnik A, Mosmann T, Howard M, O'Garra A. IL‐10 inhibits cytokine production by activated macrophages. J. Immunol. 1991 ; 147: 3815– 22.
14. 14 Norman JG, Franz MG, Fink GS et al. Decreased mortality of severe acute pancreatitis after proximal cytokineolockade. Ann. Surg. 1995 ; 221: 625– 34.
15. 15 Norman J, Franz M, Messina J et al. Interleukin‐1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 1995 ; 117: 648– 55.
16. 16 Tanaka N, Murata B, Uda K et al. Interleukin‐1 receptor antagonist modifies the changes in vital organs induced by acute necrotising pancreatitis in a rat experimental model. Crit. Care Med. 1995 ; 23: 901– 8.
17. 17 Rongione AJ, Kusske AM, Kwan K, Ashley SW, Reber HA, McFadden DW. Interleukin 10 reduces the severity of acute pancreatitis in rats. Gastroenterology 1997 ; 112: 960– 7.
18. 18 Mayer AD, McMahon MJ, Bowen M, Cooper EH. Creactive protein: An aid to assessment and monitoring of acute pancreatitis. J. Clin. Pathol. 1984 ; 37: 207– 11.
19. 19 Hahahan DJ. Platelet activating factor: A biologically active phosphoglyceride. Ann. Rev. Biochem. 1986 ; 35: 493– 509.
20. 20 Camussi G, Tetta C, Bussolino F, Caligaris‐Cappio F, Masera C, Segoloni G. Mediators of immune complex induced aggregation of polymorphonuclear neutrophils. Platelet‐activating factor as the effector substance of immune‐induced aggregation. Int. Arch. Allergy Appl. Immunol. 1981 ; 64: 25– 41.
21. 21 Kingsnorth AN, Galloway SW, Formela LJ. Randomised double‐blind phase II trial of Lexipafant, a platelet activating factor antagonist in human acute pancreatitis. Br. J. Surg. 1995 ; 82: 1414– 20.
22. 22 Fernandez del Castillo CF, Schmidt J, Rattner DW et al. Generation and possible significance of trypsinogenactivation peptides in experimental acute pancreatitis in the rat. Pancreas 1992 ; 7: 263– 70.
23. 23 Gudgeon MA, Heath DI, Hurley P et al. Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis. Lancet 1990 ; 335: 4– 8.
24. 24 Luengo L, Castillote M, Ros S, Feliu F, Vadillo J, Olona C. Clinical usefulness of the determination of the lipase/elastase ratio and of the polymorphonuclear elastase in the hospital admission of the patient with acute pancreatitis. Rev. Esp. Enferm Dig. 1996 ; 88: 551– 4.
25. 25 Ogawa M. Pancreatic secretory trypsin inhibitor as an acute phase reactant. Clin. Biochem. 1988 ; 21: 19– 25.
26. 26 Heath DI, Cruikshank A, Gudgeon M, Jehanli B, Shenkin A, Imrie CW. Role of interleukin 6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis. Gut 1993 ; 34: 41– 5.
27. 27 Inagaki T, Hoshino M, Hayakawa T et al. Interleukin 6 is a useful marker for early prediction of the severity of acute pancreatitis. Pancreas 1997 ; 14: 1– 8.
28. 28 Ueda T, Takeyama Y, Hori Y, Nishikawa J, Yamamoto M, Saitoh Y. Hepatocyte growth factor in assessment of acute pancreatitis: Comparison with C‐reactive protein and interleukin‐6. J. Gastroenterol 1997 ; 32: 63– 70.
29. 29 Ikei S, Ogawa M, Yamaguchi Y. Blood concentrations of polymorphonuclear leucocyte elastase and interleukin‐6 are indicators for the occurrence of multiple organ failures at the early stage of acute pancreatitis. J. Gastroenterol. Hepatol. 1998 ; 13: 1274– 83.
30. 30 Kingsnorth A. Role of cytokines and their inhibitors in acute pancreatitis. Gut 1997 ; 40: 1– 4.
31. 31 Buchier M, Malfertheiner P, Uhl W et al. Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993 ; 104: 1165– 70.
32. 32 Valderrma R, Perez‐Mateo M, Navarro S et al. Multicenter double‐blind trial of gabexate mesilate (FOY) in unselected patients with acute pancreatitis. Digestion 1992 ; 51: 65– 70.